Scroll

cefotaxime 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, cefalosporanic acid derivatives	546	63527-52-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cefotaxime cefotaxime sodium cephotaxime cefotaxime sodium salt	Semisynthetic broad-spectrum cephalosporin. Molecular weight: 455.46 Formula: C16H17N5O7S2 CLOGP: 0.33 LIPINSKI: 1 HAC: 12 HDO: 3 TPSA: 173.51 ALOGS: -3.49 ROTB: 8 Status: OFM Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cefotaxime
cefotaxime sodium
cephotaxime
cefotaxime sodium salt

Semisynthetic broad-spectrum cephalosporin.

Molecular weight: 455.46
Formula: C16H17N5O7S2
CLOGP: 0.33
LIPINSKI: 1
HAC: 12
HDO: 3
TPSA: 173.51
ALOGS: -3.49
ROTB: 8

Status: OFM

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
4	g	P

ADMET properties:

Show entries

Search:

Property	Value	Reference
S (Water solubility)	50 mg/mL	Bocci G, Oprea TI, Benet LZ
MRTD (Maximum Recommended Therapeutic Daily Dose)	376.38 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
EoM (Fraction excreted unchanged in urine)	30 %	Benet LZ, Broccatelli F, Oprea TI
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
CL (Clearance)	2.70 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.20 hours	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.60 %	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	0.19 L/kg	Lombardo F, Berellini G, Obach RS

Showing 1 to 8 of 8 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
March 11, 1981	FDA	SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	235.81	27.61	94	5398	33742	63449788
Toxic epidermal necrolysis	157.89	27.61	65	5427	25269	63458261
Eosinophilia	123.74	27.61	53	5439	22703	63460827
Hepatocellular injury	102.02	27.61	49	5443	27332	63456198
Premature baby	89.24	27.61	41	5451	20694	63462836
Acute generalised exanthematous pustulosis	88.34	27.61	34	5458	11065	63472465
Stevens-Johnson syndrome	87.96	27.61	43	5449	24907	63458623
Rash maculo-papular	83.55	27.61	45	5447	31851	63451679
Septic shock	81.93	27.61	58	5434	66571	63416959
Pyrexia	69.62	27.61	136	5356	470342	63013188

Showing 1 to 10 of 47 entries

Previous1 2 3 4 5Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	366.90	22.70	160	6457	32852	34917462
Hepatocellular injury	169.24	22.70	83	6534	22128	34928186
Rash maculo-papular	163.74	22.70	88	6529	28363	34921951
Toxic epidermal necrolysis	116.28	22.70	64	6553	21582	34928732
Eosinophilia	97.24	22.70	61	6556	26161	34924153
Clostridium difficile colitis	83.05	22.70	46	6571	15684	34934630
Haemophagocytic lymphohistiocytosis	74.18	22.70	40	6577	12933	34937381
Cholestasis	69.38	22.70	50	6567	26898	34923416
Hepatic cytolysis	67.36	22.70	39	6578	14457	34935857
Agranulocytosis	63.16	22.70	45	6572	23776	34926538

Showing 1 to 10 of 44 entries

Previous1 2 3 4 5Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	602.40	23.07	249	10338	63995	79669806
Hepatocellular injury	264.12	23.07	128	10459	47465	79686336
Rash maculo-papular	252.83	23.07	131	10456	55947	79677854
Toxic epidermal necrolysis	250.69	23.07	121	10466	44460	79689341
Eosinophilia	224.91	23.07	113	10474	45232	79688569
Agranulocytosis	126.00	23.07	77	10510	44953	79688848
Purpura	115.73	23.07	55	10532	19472	79714329
Acute generalised exanthematous pustulosis	109.66	23.07	51	10536	17203	79716598
Pyrexia	107.01	23.07	260	10327	678449	79055352
Cholestasis	106.14	23.07	73	10514	52036	79681765

Showing 1 to 10 of 57 entries

Previous1 2 3 4 5 6Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	J01DD01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Third-generation cephalosporins
ATC	J01DD51	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Third-generation cephalosporins
CHEBI has role	CHEBI:36047	antibacterial drugs
CHEBI has role	CHEBI:88188	allergenic drug
FDA CS	M0003827	Cephalosporins
FDA EPC	N0000175488	Cephalosporin Antibacterial
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents

Showing 1 to 8 of 8 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Streptococcal meningitis	indication	4510004	DOID:11574
Septicemia due to Escherichia coli	indication	9323009
Bacterial septicemia	indication	10001005	DOID:0040085
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Staphylococcal pneumonia	indication	22754005
Streptococcal septicemia	indication	29577008
Pneumonia due to Streptococcus	indication	34020007
Neonatal conjunctivitis	indication	34298002	DOID:9699
Pneumonia due to Pseudomonas	indication	41381004
Bacterial arthritis	indication	48245008

Showing 1 to 10 of 92 entries

Previous1 2 3 4 5…10Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.39	acidic
pKa2	13.31	acidic
pKa3	3.1	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Peptidoglycan synthase FtsI	Enzyme	FTSI_ECOLI	INHIBITOR	IC50	6.24	WOMBAT-PK	CHEMBL
Penicillin-binding protein 1A	Enzyme	PBPA_ECOLI	INHIBITOR	IC50	6.51	WOMBAT-PK	CHEMBL
Penicillin-binding protein 1B	Enzyme	PBPB_ECOLI	INHIBITOR	IC50	5.66	WOMBAT-PK	CHEMBL
Penicillin-binding protein 2	Enzyme	PBP2_ECOLI	INHIBITOR	IC50	4.62	WOMBAT-PK	CHEMBL
Beta-lactamase	Enzyme	B2ZTR6_ACIBA		Ki	6.30	CHEMBL
Beta-lactamase	Enzyme	D6NSM8_ACIBA		Ki	5.60	CHEMBL

Showing 1 to 6 of 6 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
CE3	PDB_CHEM_ID
002727	NDDF
004845	NDDF
10695961	PUBCHEM_CID
10893	IUPHAR_LIGAND_ID
203117	RXNORM
3334000	SNOMEDCT_US
372704003	SNOMEDCT_US
4018466	VANDF
4019663	VUID

Showing 1 to 10 of 26 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cefotaxime	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9930	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAMUSCULAR	ANDA	24 sections
Cefotaxime	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9931	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	24 sections
Cefotaxime	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9933	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAMUSCULAR	ANDA	24 sections
Cefotaxime	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9935	INJECTION	10 g	INTRAVENOUS	ANDA	24 sections
Cefotaxime	HUMAN PRESCRIPTION DRUG LABEL	1	21586-011	POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	Unapproved drug for use in drug shortage	2 sections
Cefotaxime	HUMAN PRESCRIPTION DRUG LABEL	1	21586-011	POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	Unapproved drug for use in drug shortage	2 sections
Cefotaxime	HUMAN PRESCRIPTION DRUG LABEL	1	21586-012	POWDER, FOR SOLUTION	2 g	INTRAMUSCULAR	Unapproved drug for use in drug shortage	2 sections
Cefotaxime	HUMAN PRESCRIPTION DRUG LABEL	1	21586-012	POWDER, FOR SOLUTION	2 g	INTRAMUSCULAR	Unapproved drug for use in drug shortage	2 sections
CEFOTAXIME	HUMAN PRESCRIPTION DRUG LABEL	1	55648-947	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAMUSCULAR	ANDA	11 sections
CEFOTAXIME	HUMAN PRESCRIPTION DRUG LABEL	1	55648-948	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAMUSCULAR	ANDA	11 sections

Showing 1 to 10 of 14 entries

Previous1 2Next